AI-Native Scoping Reviews & Evidence Mapping

Statins are not just cholesterol drugs: across an enormous evidence base, this review shows how they may help protect healthspan and longevity by lowering recurrent vascular events and mortality, while also exposing the real trade-offs around diabetes risk, intolerance, and poor long-term adherence. The full paper is worth reading because it separates where statins most clearly extend durable cardiovascular protection from where the evidence becomes mixed, controversial, and potentially relevant to broader aging-related pathways such as inflammation, liver disease, and neurocognitive decline.

This paper shows that statins remain one of the strongest cardiovascular therapies, consistently linked to fewer major events and lower mortality across very large populations, but not without trade-offs such as diabetes risk, muscle symptoms, and rises in lipoprotein(a). The full paper is worth reading because it shows where the benefit is most convincing, where the risks matter most, and how to think more clearly about the real balance between protection and harm.

This paper shows that the age gap between spouses is not just a demographic detail, but a meaningful social and health signal linked to early childbirth, women’s mental health, intimate partner violence patterns, child outcomes, widowhood, and household power dynamics across very different societies. The full review is worth reading because it reveals where larger age gaps may increase vulnerability, where they paradoxically appear protective, and how modernization is reshaping one of the most overlooked structures inside marriage.

Sports first aid remains uneven across coaches, PE teachers, athletes, and venues, with major gaps in BLS/AED readiness, dental trauma, concussion recognition, and emergency planning. This evidence map shows which practical training models, responder systems, and infrastructure strategies can strengthen real-world emergency preparedness in sport.

Retraction does not end the life of bad science — this review shows how misconduct-driven papers can keep shaping citations, clinical thinking, and public belief long after formal withdrawal. Drawing on 129 references, it maps why retractions fail, where the system breaks, and why the hidden afterlife of invalid research matters far more than most readers realize.

This review shows that rare vascular diseases are not just isolated curiosities: many are driven by shared pathways of vascular fragility, abnormal remodeling, and delayed diagnosis. It highlights where genetics, imaging, and targeted therapies are already turning rare vascular biology into practical clinical decisions.

Rural Australians have more heart disease and worse outcomes than people in metropolitan areas. Better prevention, telehealth, and regional cardiac care may help reduce this gap, but the available evidence is still insufficient.

WIfI combines true biological risk signals such as ischemia with limb-level consequences such as wound burden and infection to answer the central clinical question in PAD: is limb salvage still realistically achievable? This evidence map shows how WIfI stage translates into real-world amputation risk across clinical scenarios, and where its predictive value becomes strongest in modern decision-making.

PAD is not just a leg-artery disease — it is a powerful warning sign for future death, cardiovascular events, limb loss, and frailty. This review maps which signals matter most for prognosis, from MALE, polyvascular disease, diabetes and CKD to biomarkers, nutrition scores, exercise capacity, and machine-learning risk prediction.

This review shows that PAD is not a niche vascular diagnosis but a massive, underrecognized global burden that concentrates sharply in diabetes, kidney disease, stroke, and other high-risk populations while often remaining clinically silent. The full read is worth it because it maps where PAD prevalence is truly highest, why reported rates vary so widely, and which patient groups should trigger much earlier ABI-based case finding.

PAD is not just blocked arteries — this review shows it as a biologically complex disease driven by endothelial failure, oxidative stress, metabolic myopathy, mitochondrial dysfunction, and emerging signals from gut metabolites, extracellular vesicles, and non-coding RNA pathways. The full read is worth it because it maps where the strongest mechanistic evidence lies, which biomarkers may matter next, and which pathophysiologic signals could reshape future PAD diagnostics and targeted therapy.

PAD is not just undertreated — it is systematically undertreated despite repeated signals that proper medication changes survival, cardiovascular risk, and limb outcomes. This review shows where the real gaps are, which therapies carry the strongest signal, and why better discharge and follow-up prescribing may be one of the most actionable opportunities in vascular care.